Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicine – More >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 1.78 (1.97%)
Intraday High$92.60
Intraday Low$88.87
Data as of 04/24/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
04/23/15Clovis Oncology to Announce First Quarter 2015 Financial Results and Host Webcast Conference Call on May 6
BOULDER, Colo.--(BUSINESS WIRE)--Apr. 23, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2015 financial results on Wednesday, May 6, 2015, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis O... 
Printer Friendly VersionDownload PDF
04/06/15Clovis Oncology Receives Breakthrough Therapy Designation for Rucaparib for Monotherapy Treatment of Advanced Ovarian Cancer in Patients with BRCA-mutated Tumors (Inclusive of both Germline and Somatic BRCA Mutations)
Only PARP inhibitor to receive Breakthrough Therapy designation Rucaparib NDA filing for treatment of advanced platinum-sensitive ovarian cancer planned for 2016 Second Breakthrough Designation granted to a Clovis Oncology drug candidate BOULDER, Colo.--(BUSINESS WIRE)--Apr. 6, 2015-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has granted... 
Printer Friendly VersionDownload PDF
02/25/15Clovis Oncology Announces 2014 Operating Results
Rociletinib (CO-1686) NDA and MAA submissions for EGFR-mutant lung cancer planned mid-2015 Rucaparib development program accelerated; filing now planned for treatment of platinum-sensitive ovarian cancer in 2016 BOULDER, Colo.--(BUSINESS WIRE)--Feb. 25, 2015-- Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for its quarter and year ended December 31, 2014, and provided an update on the Compan... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
4:30 p.m. ET
Q1 2015 Clovis Oncology, Inc. Earnings Conference Call
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.